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Background: Few studies have used quantitative polymerase chain reaction (qPCR) as an approach to measure
virus neutralization assay endpoints. Its lack of use may not be surprising considering that sample nucleic acid
extraction and purification can be expensive, labor-intensive, and rate-limiting.
Methods: Virus/antibody mixtures were incubated for one hour at 37°C and then transferred to Vero cell
monolayers in a 96-well plate format. At 24 (or 48) hours post-infection, we used a commercially available reagent
to prepare cell lysates amenable to direct analysis by one-step SYBR Green quantitative reverse transcription PCR
using primers specific for the RSV-N gene, thereby obviating the need for cumbersome RNA extraction and
purification. The neutralization titer was defined as the reciprocal of the highest dilution needed to inhibit the PCR
signal by 90% when compared with the mean value observed in virus control wells in the absence of neutralizing
antibodies.
Results: We have developed a qPCR-based neutralization assay for human respiratory syncytial virus. Due to the
sensitivity of qPCR in detecting virus replication, endpoints may be assessed as early as 24 hours post-infection. In
addition, the dynamic range of qPCR provides a basis for the assay to be relatively robust to perturbations in input
virus dose (i.e., the assay is in compliance with the Percentage Law).
Conclusions: This qPCR-based neutralization assay is suitable for automated high-throughput applications. In
addition, our experimental approach may be generalizable for the rapid development of neutralization assays for
other virus families.
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SYBR GreenBackground
Human respiratory syncytial virus (RSV), an enveloped RNA
virus of the Paramyxoviridae family, is a pathogen of primary
importance that can cause severe respiratory illness associ-
ated with high hospitalization rates and excess morbidity/
mortality in susceptible populations such as infants, children,
and the elderly [1-3]. RSV circulating among humans can be
broadly categorized into two antigenic subgroups (A and B)
[4]. The high prevalence of RSV results in most individuals* Correspondence: haruhiko.murata@fda.hhs.gov
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reproduction in any medium, provided the orbeing exposed as children within the first two years of life,
and thereafter, recurrent infections can take place through
adulthood [5]. Effective pharmacotherapy for RSV currently
remains limited. The nucleoside analogue ribavirin is the
only approved drug for RSV infection, but its clinical use is
infrequent due to marginal efficacy [6]. A humanized mono-
clonal antibody with RSV-neutralizing activity is only li-
censed for prophylaxis in infants at high risk for severe RSV
disease [7]. No vaccine is available for the prevention of RSV
infection despite efforts spanning several decades [8-10].
Notable in the history of RSV vaccine development is the
phenomenon of disease enhancement observed in recipients
of a formalin-inactivated RSV vaccine formulation duringLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prominent example of the complexity that can be encoun-
tered during the course of vaccine development.
Serum neutralizing antibodies play an important role in
conferring protection against RSV infection [7,15-17]. Trad-
itional methods for measuring RSV-neutralizing activity in
biological samples are labor-intensive and time-consuming.
Plaque-reduction neutralization (PRN) entails numerous
manipulation steps that hinder throughput, and plaque
visualization can require several days [18]. Microneutra-
lization assays for RSV using endpoint assessments based
on ELISA [19], automated plaque counting [20,21], spec-
trophotometric quantification of cell viability [22], or en-
zymatic measurement of a reporter activity [23] require
post-infection durations of 2–5 days. A recently developed
neutralization assay for RSV based on using flow cytometry
to evaluate infection by GFP-expressing RSV reporter vi-
ruses can measure the endpoint at 18 hours post-infection
[24]; however, this assay requires a sophisticated instrument
(a flow cytometer) that may preclude broad accessibility for
interested investigators. Thus, a need still exists for a sim-
ple, rapid microneutralization assay suitable for high-
throughput applications. Such an assay might be a useful
tool to facilitate RSV vaccine development since one can
anticipate the need to test thousands of samples to identify
RSV susceptibles prior to immunization and to assess im-
mune responses afterwards.
Quantitative PCR (qPCR) is associated with a number of
appealing features, particularly in terms of robustness, sensi-
tivity, and dynamic range. However, to date, few studies have
used this experimental approach to quantify the extent of
virus neutralization [25,26]. Normally, the need for RNA/
DNA purification from samples represents a significant con-
straint that can decrease throughput in qPCR-based assays.
We recently developed a qPCR-based neutralization assay
for influenza virus by making use of a commercial reagent
that allows the generation of PCR-ready cell lysates with
minimal effort, thus circumventing a previously rate-limiting
technical obstacle [27]. In the present study, we have
exploited the sensitivity afforded by qPCR to develop a rapid
96-well format microneutralization assay for RSV with an as-
sessment of endpoint as early as 24 hours post-infection. In
addition, the dynamic range intrinsic to qPCR allows this
assay to be relatively robust to perturbations in input virus
dose. Considering the relative ease of generating experimen-
tal samples for analysis as well as the possibility for relying
on automation to prepare qPCR plates, this assay might be
appropriate for high-throughput purposes.
Results
qRT-PCR performance parameters
Two pairs of SYBR Green qPCR primers, each targeting
a conserved region of the N gene of RSV subgroup A or
B [28], were used in our study. Purified total RNAstandards from Vero cells infected with either RSV-A2
(subgroup A) or RSV-B1 (subgroup B) were prepared for
the purpose of testing the performance features of our
one-step quantitative reverse transcription SYBR Green
PCR (qRT-PCR). In order to improve comparability with
experimental samples, the purified RNA standards were
serially diluted (10-fold) using a relevant matrix as the
diluent. This matrix consisted of a lysate of uninfected
Vero cells prepared using the Bio-Rad iScript Sample
Preparation Reagent (subsequently referred to as Bio-
Rad SPR). One μL of each dilution was subjected to
one-step qRT-PCR in a total assay volume of 10 μL. An
automated liquid-handling system was routinely used in
the preparation of reactions for our study. Typical re-
sults are shown in Figures 1A (RSV-A2 RNA dilution
series) and 1B (RSV-B1 RNA dilution series). PCR effi-
ciency was ~85% for RSV subgroup A primers and ~98%
for RSV subgroup B primers; for both primer pairs, lin-
earity was observed over at least a 5 log10 range. RNA
standards were used in subsequent experiments to verify
the performance of each PCR run and to facilitate the
quantification of experimental samples.
Replication kinetics of RSV assessed by qRT-PCR
Replication of RSV was assessed by qRT-PCR using cells
infected in 96-well culture plates. Vero cells were seeded
overnight (15,000 cells per well) and on the following
day infected with 500 TCID50 per well of RSV-A2 or
RSV-B1. After incubation for 1 hour at 37°C, the cells
were washed twice with PBS (100 μL per well) to remove
unbound virus; subsequently, the culture medium (200
μL per well) was replaced, and the infection was allowed
to proceed at 37°C. Every 24 hours, cell lysates were pre-
pared using Bio-Rad SPR according to the following sim-
ple steps: (1) remove the culture medium and wash the
cells twice with 100 μL of PBS; (2) apply 100 μL of Bio-
Rad SPR per well and incubate at room temperature for
1 min; and (3) collect the resulting lysate and freeze
at −20°C until assessment by qRT-PCR. The replication
kinetics of RSV-A2 and RSV-B1 are shown in Figure 2.
RNA copy numbers were normalized to the mean value
obtained 24 hours post-infection. For both RSV-A2 and
RSV-B1 strains, the PCR signal increased by approxi-
mately 105-fold over the course of 96 hours. In addition,
an amplification of >1000-fold was observed for both
virus strains over the initial 24 hours. The data support
the feasibility of assessing virus neutralization at 24
hours post-infection.
Correspondence of qPCR signal and input virus dose
The ability to distinguish two-fold differences in virus input
was assessed. Vero cells were seeded overnight (15,000 cells
per well), and on the following day, monolayers were infected
with inocula derived from two-fold dilution series of RSV-A2



























































Figure 1 SYBR Green qRT-PCR targeting the RSV N gene. Total
RNA was purified from Vero cells infected with either RSV-A2 or
RSV-B1. The resulting RNA standards were serially diluted (10-fold); a
cell lysate, prepared from uninfected Vero cells with the Bio-Rad
iScript Sample Preparation Reagent (Bio-Rad SPR), was used as the
diluent (the initial dilution contained ~10 ng/μL of RNA standard).
One μL of each dilution was subjected to one-step SYBR Green qRT-
PCR (10 μL total reaction volume). Mean threshold cycle (Ct; n = 2) is
plotted against log10 (RNA dilution factor) for each RNA standard
dilution series: (A) RSV-A2 RNA and (B) RSV-B1 RNA.






























Figure 2 Replication kinetics of RSV. Vero cells were seeded in
96-well culture plates (15,000 cells per well). On the following day,
cells were infected with RSV-A2 or RSV-B1 (500 TCID50 per well).
After incubation for 1 hour at 37°C, the cells were washed twice
with PBS to remove unbound virus; subsequently, the culture
medium was replaced and the infection was allowed to proceed at
37°C. At the indicated times, cell lysates were prepared using
Bio-Rad SPR and subjected to one-step SYBR Green qRT-PCR. RNA
copy numbers were normalized to the mean value obtained at 24
hours post-infection for each virus strain. Each point represents the
mean with corresponding range (n = 3).
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TCID50 per well). At 24 hours post-infection, cell lysates
were prepared using Bio-Rad SPR and subjected to qRT-
PCR analysis. RNA copy numbers were normalized to the
mean value obtained with the most dilute input (78 TCID50for RSV-A2 and 490 TCID50 for RSV-B1). Reasonable linear-
ity was observed across the entire range of virus input for
both RSV-A2 (Figure 3A) and RSV-B1 (Figure 3B). The data
suggest that relatively small variations in infectivity (two-fold)
can be measured with our approach.qRT-PCR-based microneutralization assay for RSV (qPCR-
MN)
A qRT-PCR-based microneutralization assay for RSV
(qPCR-MN) was performed to assess the neutralization
activity associated with a pooled human immunoglobulin
reference standard (designated as RSV-Lot 1) at a working
concentration of 1% (1 mg/100 μL). Vero cells were seeded
overnight (15,000 cells per well); on the following day, the
virus inoculum (500 TCID50 per well of RSV-A2 or RSV-
B1) was mixed with an equal volume from a two-fold dilu-
tion series of RSV-Lot 1 and incubated for 1 hour at 37°C.
After incubation, the virus/immunoglobulin mixture was
transferred to corresponding wells on a 96-well plate
containing Vero cell monolayers. At 24 or 48 hours post-
infection, cell lysates were prepared using Bio-Rad SPR and
subjected to qRT-PCR analysis. The results are shown in
A RSV-A2































































Figure 3 qPCR signal vs. input virus dose. Vero cells were seeded
in 96-well culture plates (15,000 cells per well). On the following day,
each well was infected with an inoculum from a two-fold dilution
series: 40,000 to 78 TCID50 per well for (A) RSV-A2, and 250,000 to
490 TCID50 per well for (B) RSV-B1. At 24 hours post-infection, cell
lysates were prepared using Bio-Rad SPR and subjected to qRT-PCR
analysis. RNA copy numbers were normalized to the mean value
obtained with the most dilute virus input. Each point represents the
mean with corresponding range (n = 4).
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value obtained from virus-infected wells in the absence of
neutralizing immunoglobulin (virus control wells). Repre-
sentative neutralization experiments consisting of three ex-
perimental replicates (reflecting three independent RSV-Lot
1 dilution series) are shown in Figures 4A (RSV-A2) and 4B
(RSV-B1). The neutralization titer was defined as the recip-
rocal of the highest dilution factor of RSV-Lot 1 necessary
to inhibit the PCR signal by 90% (i.e., below the threshold
of 10% of the mean value observed in virus control wells).
For both virus strains, the PCR signal decreased in a dose-
dependent manner as the concentration of neutralizing
antibodies increased; at maximal neutralization, the PCR
signal was inhibited by >1000-fold. For both RSV-A2 and
RSV-B1, similar results were obtained at 24 and 48 hours
post-infection. Thus, while we have developed our assay
with the intention of routinely assessing the neutralization
endpoint at 24 hours post-infection, our data suggest that
perturbations in assay duration can be tolerated to a certain
extent (24 h vs. 48 h).
Each individual experimental replicate can be used to
derive an independent estimate of the neutralization titer.
The individual results of each replicate for the experi-
ments shown in Figures 4A and 4B are shown in
Figures 4C (RSV-A2) and 4D (RSV-B1); the mean of the
curves depicted in Figure 4C would result in Figure 4A,
while the mean of the curves depicted in Figure 4D would
result in Figure 4B. For RSV-A2 neutralization, the geo-
metric mean titer (GMT) calculated from experimental
replicates for RSV-Lot 1 (1% concentration) was 156
assessed at 24 hours post-infection (7 experiments, each
with 3 experimental replicates; n = 21) and 161 assessed at
48 hours post-infection (3 experiments, each with 3
experimental replicates; n = 9). Likewise for RSV-B1
neutralization, the GMT was 197 assessed at 24 hours
post-infection (n = 21) and 299 assessed at 48 hours post-
infection (n = 9). In comparison, the GMTs from plaque-
reduction neutralization (PRN) for RSV-Lot 1 (at day 5
post-infection; assessed in HEp-2 cells for RSV-A2 or Vero
cells for RSV-B1) in the absence of guinea pig complement
were 238 and 450 against RSV-A2 and RSV-B1, respect-
ively, while the PRN GMTs in the presence of guinea pig
complement were 1176 and 2046 against RSV-A2 and
RSV-B1, respectively.
Neutralization experiments with RSV-A2 assessed at 24
hours post-infection were also performed with a mono-
clonal antibody ascites fluid with known specificity to the
RSV F protein (1200) [29] as well as rabbit serum samples
generated pre- and post-immunization with UV-inac-
tivated RSV-A2. The results are shown in Figure 4E. The
GMTs (n = 3) were <32, 128, and 645 for pre-immune
rabbit serum, post-immune rabbit serum, and monoclonal
antibody 1200, respectively. The data suggest that the
antibody-dependent decrease in signal observed in qPCR-















































































RSV-A2 24h Replicate 1
RSV-A2 24h Replicate 2
RSV-A2 24h Replicate 3
RSV-A2 48h Replicate 1
RSV-A2 48h Replicate 2


































RSV-B1 24h Replicate 1
RSV-B1 24h Replicate 2
RSV-B1 24h Replicate 3
RSV-B1 48h Replicate 1
RSV-B1 48h Replicate 2
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Figure 4 qRT-PCR-based microneutralization of RSV (qPCR-MN). Vero cells were seeded in 96-well culture plates (15,000 cells per well). On
the following day, a two-fold dilution series was prepared from a pooled human immunoglobulin reference standard (designated as RSV-Lot 1)
starting from an initial concentration of 1%. The virus inoculum (500 TCID50 per well of RSV-A2 or RSV-B1) was mixed with an equal volume of
RSV-Lot 1 dilution and incubated for 1 hour at 37°C. After incubation, the mixture was transferred to the plate of seeded Vero cells. At 24 or 48
hours post-infection, cell lysates were prepared using Bio-Rad SPR and subjected to qRT-PCR analysis. RNA copy numbers were normalized to the
mean value obtained from virus-infected control wells in the absence of neutralizing immunoglobulin. The neutralization titer was defined as the
reciprocal of the highest dilution factor of RSV-Lot 1 necessary to inhibit the PCR signal by 90% (or below the threshold of 10% of the virus
control wells indicated by the dotted line). (A) RSV-A2 neutralization assessed at 24 or 48 hours post-infection (each point represents the mean;
n = 3). (B) RSV-B1 neutralization assessed at 24 or 48 hours post-infection (each point represents the mean; n = 3). The individual experimental
replicates assessed independently (n = 3) are shown for neutralization experiments with (C) RSV-A2 and (D) RSV-B1. Additional neutralization
experiments (E) with RSV-A2 assessed at 24 hours post-infection were also performed with a monoclonal antibody with known specificity to the
RSV F protein (1200) as well as rabbit sera generated pre- and post-immunization with RSV-A2 (each point represents the mean with
corresponding range; n = 3).
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Figure 5 Compliance with the Percentage Law. Vero cells were
seeded in 96-well culture plates (15,000 cells per well). On the
following day, a two-fold dilution series was prepared from the
human immunoglobulin standard (RSV-Lot 1) starting from an initial
concentration of 1%. The virus inoculum (100, 500, 2500, 12500
TCID50 per well of RSV-A2 or RSV-B1) was mixed with an equal
volume of RSV-Lot 1 dilution and incubated for 1 hour at 37°C. After
incubation, the mixture was transferred to Vero cell monolayers. At
24 hours post-infection, cell lysates were prepared using Bio-Rad SPR
and subjected to qRT-PCR analysis. RNA copy numbers were
normalized to the mean value obtained from virus-infected control
wells in the absence of neutralizing immunoglobulin. Each point
represents the mean ± SEM from 3 experiments with 3 experimental
replicates (n = 9) for (A) RSV-A2 neutralization and (B)
RSV-B1 neutralization.
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RSV.
Compliance with the Percentage Law
According to the Percentage Law [30,31], the proportion
of infectivity neutralized by a given concentration of anti-
bodies remains constant over a wide range of virus input,
provided that the concentration of antibodies is in vast
molar excess over the concentration of virus (a reasonable
assumption under most experimental conditions). We
assessed the compliance of our neutralization assay with
the Percentage Law. Neutralization by pooled human im-
munoglobulin (RSV-Lot 1 at an initial concentration of
1%) was assessed at 24 hours post-infection using 100,
500, 2500, or 12500 TCID50 per well as virus inputs. The
results are shown in Figures 5A (RSV-A2 neutralization)
and 5B (RSV-B1 neutralization). For both RSV-A2 and
RSV-B1, similar neutralization results were obtained re-
gardless of input virus dose. The GMTs (3 experiments,
each with 3 experimental replicates; n = 9) were 219, 149,
138, and 118 for RSV-A2 neutralization at 100, 500, 2500,
or 12500 TCID50, respectively. The GMTs (n = 9) were
256, 174, 188, and 188 for RSV-B1 neutralization at 100,
500, 2500, or 12500 TCID50, respectively. Thus, qPCR-
MN appears to be reasonably robust to perturbations in
input virus across a >100-fold range, thereby demonstrat-
ing a performance feature predicted on the basis of the
Percentage Law.
Non-specific inhibition of RSV replication and
neutralization assay limit of detection
Non-specific inhibitory effects of human serum might
limit the ability to detect low RSV-neutralizing activity.
Immunoglobulin-depleted human serum was obtained
from a commercial source and tested in our assay. The
use of immunoglobulin-depleted human serum was ne-
cessary because of the difficulty in procuring serum sam-
ples from individuals truly naive to RSV exposure. The
results are shown in Figures 6A (RSV-A2) and 6B (RSV-
B1). For dilutions of depleted serum at or exceeding
1:16, marginal inhibition of virus replication was ob-
served (PCR signal exceeded 80% of mean values ob-
served in virus control wells). At higher concentrations
of depleted serum, substantial inhibition of RSV replica-
tion was observed (PCR signal less than 30% of values
observed in virus control wells for both RSV-A2 and
RSV-B1 at a dilution of 1:4). Assuming that the tested
immunoglobulin-depleted serum is representative of
negative serum samples obtainable from an exposure-
naive (hypothetical) population, routine assessment of a
human serum sample might require an initial dilution of
1:16 or greater.
We sought to investigate the assay limit of detection
further by analyzing samples generated by spiking theimmunoglobulin-depleted human serum with the refer-
ence pooled human immunoglobulin RSV-Lot 1. For the
initial spiked sample, RSV-Lot 1 at 10% concentration was




























































































































































Figure 6 Non-specific inhibition of RSV in minimally diluted samples. Immunoglobulin-depleted human serum was assessed in qPCR-MN
(Vero cells; 500 TCID50 per well of virus input; assessment at 24 hours post-infection) with (A) RSV-A2 and (B) RSV-B1. Values represent the
mean ± SD (n = 9). Spiking experiments were also performed using the human immunoglobulin standard RSV-Lot 1. For the initial spiked sample,
RSV-Lot 1 at 10% concentration was diluted 1:10 in immunoglobulin-depleted human serum. Five additional samples were generated by two-fold
serial dilution using the depleted serum as the diluent. The resulting samples with simulated low neutralizing activity were assessed by qPCR-MN
with (C) RSV-A2 and (D) RSV-B1. The observed GMT (n = 3) is plotted against the dilution factor of the simulated sample.
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pleted serum as the diluent. In this manner, we generated
serum samples with simulated low neutralizing activity.
The results of analyzing these samples are shown in
Figures 6C (RSV-A2) and 6D (RSV-B1). The observed GMT
(n = 3) is plotted against the dilution factor experienced by
the simulated sample. For RSV-B1 (Figure 6D), a reasonably
linear relationship was observed across the sample dilution
range. Thus, the observed titer was generally in agreement
with the expected titer. For RSV-A2 (Figure 6C), a linear re-
lationship was observed until the sample experienced a dilu-
tion of 16-fold (observed GMT of 13); beyond this dilution,
a departure from linearity was observed. The data suggest
that, under some experimental conditions, non-specific in-
hibitory effects of the sample matrix might limit the ability
to accurately detect low neutralizing activity.Correlation between titers measured by qPCR-MN and
PRN
We subjected archived human serum samples (n = 30;
obtained from children who participated in a measles
vaccine study in the 1980’s) to analysis by qPCR-MN
and PRN in the absence or presence of 5% guinea pig
complement. Neutralization against RSV-A2 was evalu-
ated. PRN was performed using HEp-2 cells. For
qPCR-MN (performed using Vero cells), 5% guinea pig
complement was included in the neutralization reaction
as necessary without altering other assay parameters or
procedures. Final serum sample dilutions for qPCR-MN
ranged from 1:32 to 1:8192; sera with qPCR-MN titers
<32 (n = 2 in the absence of complement; n = 1 in the
presence of complement) were assigned a titer of 16
for this analysis. The correlation coefficients were 0.87
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Figure 7 Correlation between qPCR-MN and plaque-reduction
neutralization (PRN). Neutralization assays were performed in the
(A) absence or (B) presence of 5% guinea pig complement with
RSV-A2 using a panel of human serum samples (n = 30). PRN was
performed using HEp-2 cells (50% inhibition endpoint). qPCR-MN
(90% inhibition endpoint; geometric mean titers calculated from two
experimental replicates) was performed using Vero cells (500 TCID50
per well of virus input; assessment at 24 hours post-infection).
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ence of guinea pig complement, respectively. The pres-
ence of guinea pig complement increased the observed
titers for both assays. GMTs across samples (n = 30)
were 268 and 440 for PRN (50% inhibition endpoint) in
the absence or presence of guinea pig complement, re-
spectively. Similarly, GMTs (n = 30) were 69 and 199 for
qPCR-MN (90% inhibition endpoint) in the absence or
presence of guinea pig complement, respectively.
Discussion
We have developed a simple qRT-PCR-based microneu-
tralization assay for RSV (qPCR-MN). The crux of our
approach is the use of a commercially available reagent
(Bio-Rad SPR) to generate cell lysates that are amenable to
direct analysis by qRT-PCR, thereby allowing us to avoid
the need for RNA extraction and purification (which nor-
mally can be laborious and rate-limiting). Certain features
intrinsic to qPCR offer significant advantages in the context
of our study. The sensitive detection of RSV replication al-
lows our qPCR-MN neutralization endpoint to be assessed
at 24 hours post-infection (and likely earlier). In addition to
time-saving benefits, a shorter assay duration is preferable a
priori when assessing the neutralization of replication-
competent viruses because it minimizes possible distortions
associated with multiple cycles of virus replication (as dis-
cussed in our earlier study on influenza virus neutralization
[27]). The dynamic range of qRT-PCR (at least 5 log10
range; Figure 1) directly contributes to qPCR-MN being
relatively robust to perturbations in input virus dose and al-
lows the empirical demonstration of compliance with the
Percentage Law (Figure 5) without the need to dilute or
otherwise manipulate reactions in order to quantify the ex-
tent of virus neutralization. Other logistically desirable attri-
butes of qPCR-MN include the feasibility of incorporating
automation for the preparation of qRT-PCR and the ease of
standardization across independent laboratories through
dissemination of frozen RNA reagents and samples.
We also wish to emphasize the flexibility of our ap-
proach. We generated data for our study using two virus
strains (RSV-A2 and RSV-B1). However, the qPCR primer
pairs used in our study (targeting the conserved N gene)
should be immediately applicable to a diverse range of
virus strains and field isolates without the need for major
adjustments in assay parameters. The performance of a
nucleic acid-based assay targeting a conserved region of
the viral genome might be more predictable across a wider
range of strains than assays relying on other RSV-specific
detection reagents such as antibodies. As an example, the
monoclonal antibody A3, used as a detection reagent in
ELISA-based microneutralization assays for influenza
virus, exhibits a range in its sensitivity to detect the nu-
cleoprotein (NP) from influenza A viruses that varies over
at least two orders of magnitude despite the high degreeof conservation of NP [32]. Thus, qPCR-MN might be a
useful tool to dissect subtle antigenic differences within
the subgroups of RSV. In addition, although we primarily
used Vero cells to generate data for our study, our ap-
proach does not preclude the use of other cell lines. For
example, we were successful in performing qPCR-MN for
RSV using HEp-2 cells (data not shown). The suitability of
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particular to a given experiment (for example, the growth
property of the RSV strain).
The current cost (~$1 per qRT-PCR well) associated
with qPCR-MN (mainly due to Bio-Rad SPR as well as
the commercial kit for one-step qRT-PCR) might be ac-
ceptable for many purposes, even ones requiring high
sample throughput, especially considering the relatively
minimal effort necessary for generating suitable experi-
mental samples for qRT-PCR analysis and the possibility
for exploiting automation. For example, screening serum
samples using a single dilution to identify RSV suscep-
tible subjects for inclusion in clinical trials might be
feasible with this type of assay since only a small volume
of serum is required and since the assay potentially pro-
vides a rapid determination of serostatus. We are ac-
tively investigating additional cost-cutting measures
including further downscaling and substitution of key re-
agents associated with substantial expense (i.e., Bio-Rad
SPR) with less costly alternatives.
We have used a 90% inhibition endpoint for qPCR-
MN in the present study. A 50% inhibition endpoint
resulted in greater variability in neutralization titer esti-
mation among replicates compared with the use of a
90% inhibition endpoint. Other endpoint definitions (for
example, a 50% inhibition endpoint calculated according
to a non-parametric algorithm based on the method of
Spearman and Kärber) could be used, but the correlation
of results with PRN titers (using a 50% inhibition end-
point) marginally decreased (data not shown). In future
studies, the endpoint definition for qPCR-MN might
need to be refined using larger sample sizes from diverse
populations in order to identify a biologically relevant
neutralization threshold that accurately discriminates be-
tween RSV-susceptible and RSV-protected individuals. It
is important to note that there may be intrinsic differ-
ences in the functional activity of the antibodies evalu-
ated in an assay that measures 90% inhibition within a
single virus infection cycle as compared with an assay
that measures 50% reduction in plaque counts following
multiple cycles of virus replication. These qualitative dif-
ferences could contribute to the minor differences in re-
sults observed between qPCR-MN and PRN.
Conclusions
We have developed a simple qRT-PCR-based micro-
neutralization assay (qPCR-MN) for RSV amenable to high-
throughput applications. Our approach relies upon a
commercially available reagent that circumvents sample
RNA purification, thereby removing a procedural obstacle
that can be labor-intensive and rate-limiting. Reagents that
require the expenditure of substantial time or resources
to generate (reporter virus constructs for different strains,
antibodies, etc.) are not necessary for qPCR-MN. Thesensitivity and dynamic range of qRT-PCR can be exploited
to allow neutralization endpoint assessment at 24 hours
post-infection as well as empirical demonstration of com-
pliance with the Percentage Law (i.e., robustness to pertur-
bations in input virus dose). Other appealing features of
qPCR-MN include the possibility for incorporation of auto-
mation and the availability of the option to disseminate fro-
zen RNA reagents and samples for the purpose of assay
standardization. Finally, we note that our qRT-PCR-based
approach might be generalizable for the rapid development
of neutralization assays involving other families of viruses.
Methods
Viruses, cells, and antibodies
RSV-A2, a gift from Robert Chanock and Brian Murphy
(NIAID, NIH, USA), was serially plaque-purified 3 times
and then amplified in HEp-2 cells to generate the working
virus pool. RSV-B1, a gift from Fran Rubin (NIAID, NIH),
was amplified in Vero cells after receipt to generate the
working virus pool. HEp-2 and Vero cells (obtained from
ATCC; Manassas, VA, USA) were grown in Eagle’s MEM
supplemented with 4 mM glutamine and 10% fetal bovine
serum (MEM-10); RSV infections were performed with
MEM supplemented with 4 mM glutamine and 1% fetal
bovine serum (MEM-1) as described [33]. Extracellular
virus was harvested when the observed cytopathic effect
(CPE) reached 4+ (72 to 120 hours after infection; MOI of
0.1), clarified by low-speed centrifugation and stabilized by
addition of 100 mM MgSO4 and 50 mM HEPES buffer,
and stored at −70°C in aliquots until use. For animal im-
munizations, RSV-A2 was purified using a 30/45/60% dis-
continuous sucrose gradient with ultracentrifugation at
35K RPM in a Beckman SW41 rotor for 2 hours at 4°C.
The purified virus fraction was inactivated by exposure to
ultraviolet light (254 nm) for 30 minutes as described [34],
and inactivation was confirmed by absence of CPE follow-
ing incubation on Vero cell monolayers for 6 days.
A lot of human immunoglobulin (intended for intravenous
human administration) was obtained from Baxter (Deerfield,
IL, USA). Following extensive characterization (J. Beeler;
manuscript in preparation), this lot was designated as “RSV-
Lot 1” to be used as a reference reagent. RSV-F monoclonal
antibody 1200 (ascites fluid) with known neutralizing activity
was generated and characterized as previously described [29].
Rabbit anti-RSV polyclonal sera were prepared by immuniz-
ing New Zealand white rabbits subcutaneously with a dose
equivalent of 106 TCID50 of UV-inactivated, purified RSV-A2
in complete Freund’s adjuvant; rabbits were boosted two
times with the same dose in incomplete Freund’s adjuvant
every three weeks. This protocol was approved by the CBER
Institutional Animal Care and Use Committee (IACUC;
FDA, USA). Pre-immune sera were collected before the first
immunization, and post-immune sera were collected four
weeks after the last boost. Archived, de-identified human
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pated in a measles vaccine study in the 1980’s were assessed
following approval from the Research Involving Human Sub-
jects Committee (RIHSC; FDA, USA). Human serum de-
pleted of IgG, IgM, and IgA was obtained from SunnyLab
(SF142-2; Sittingbourne, UK). For certain neutralization
experiments, the antibody samples were assessed in the pres-
ence of guinea pig complement (C200-0005; Rockland Im-
munochemicals, Inc.; Gilbertsville, PA, USA) at 5% in the
final virus/antibody mixture (complement/antibody sample
dilution mixed with an equal volume of virus).
qRT-PCR-based microneutralization assay (qPCR-MN) for
RSV
RNA standards were prepared by purifying total RNA
(using the Qiagen RNeasy kit; Valencia, CA, USA) from
Vero cells infected with RSV-A2 or RSV-B1 (MOI = 0.1;
72 hours post-infection).
For qPCR-MN, 96-well culture plates were seeded with
Vero cells (15,000 cells per well). On the following day,
the cell propagation medium (MEM-10) was replaced with
the infection medium (MEM-1; 100 μL/well). Virus inoc-
ula were mixed with an equal volume of antibody dilutions
(from a dilution series using MEM-1 as the diluent) and
incubated at 37°C for 1 h; subsequently, 100 μL of the
virus/antibody mixtures (containing a pre-neutralization
infectivity of 500 TCID50 of RSV-A2 or RSV-B1) were
transferred to the corresponding wells containing cell
monolayers. At 24 h post-infection, experimental samples
were prepared using the iScript Sample Preparation Re-
agent (Bio-Rad; Hercules, CA, USA; referred to as Bio-
Rad SPR) by (1) removing the medium and washing the
cells twice with 100 μL of PBS; (2) applying 100 μL of Bio-
Rad SPR per well and incubating at room temperature for
1 min; and (3) collecting the resulting lysate. Sample ly-
sates were routinely stored frozen at −20°C until assess-
ment by qRT-PCR.
The following two primer pairs (targeting the RSV N
gene) were used for qRT-PCR: CATCCAGCAAATA
CACCATCCA and TTCTGCACATCATAATTAGGAG
TATCAA for RSV subgroup A viruses, and CTGTCATC
CAGCAAATACACTATTCA and GCACATCATAATT
GGGAGTGTCA for RSV subgroup B viruses [28]. Fol-
lowing optimization (performed as described previously
[35]), reactions contained: each primer at 300 nM, 1X
iScript One-Step SYBR Green RT-PCR mix (Bio-Rad),
1 μL of sample (Bio-Rad SPR lysate), and water to 10 μL.
Reaction preparations were routinely performed using
the epMotion 5075 automated liquid handling system
(Eppendorf North America; Hauppage, NY, USA). Real-
time PCR was performed using the CFX-96 instrument
(Bio-Rad) using the following conditions: 50°C for 10
min (1X)/ 95°C for 5 min (1X)/ 95°C for 10 s, 63°C (for
RSV subgroup A primers) or 64°C (for RSV subgroup Bprimers) for 30 s (40X). The RNA standards (serially di-
luted in a Bio-Rad SPR lysate prepared from uninfec-
ted Vero cells) were used to verify the performance of
each PCR run and to facilitate the quantification of
experimental samples. The RNA copy numbers were
normalized to the mean value (n ≥ 3) obtained from
virus-infected control wells in the absence of neutraliz-
ing antibodies (virus control wells). The neutralization
titer was defined as the reciprocal of the highest dilution
factor (after accounting for addition of virus) necessary
to inhibit the PCR signal 90% (i.e., below the threshold
of 10% of the mean value observed in virus control
wells). Certain assay parameters (for example, input
virus dose and incubation time) were altered as indicated
without other assay adjustments.
Plaque-reduction neutralization assay (PRN) for RSV
Plaque-reduction neutralization assays (PRN) were
performed as previously described [18]. Human serum
samples were heat inactivated at 56°C for 30 minutes
prior to testing. Briefly, serial four-fold dilutions of anti-
body samples were incubated with RSV-A2 or RSV-B1
in the presence or absence of 5% guinea pig complement
(diluted to yield 25–35 plaques per well) for 1 hour prior
to inoculating virus/antibody mixtures onto HEp-2 cell
monolayers in duplicate in 24-well cell culture plates for
one hour at 37°C prior to overlaying with medium
containing 1.5% methylcellulose. After 5 days, mono-
layers were fixed using 80% methanol and subjected to
immunostaining with a mixture of two RSV-F monoclo-
nal antibodies (1129 and 1243) [29]. Plates were then
washed 3 times with PBS followed by addition of
peroxidase-conjugated, goat anti-mouse antibody for 1
hour at 37°C. Plates were washed, treated with 100 μL of
4-chloro-1-naphthol in methanol (3 mg/mL) and 0.01%
hydrogen peroxide until plaques were obvious to the eye
with minimal background. Endpoint titers were calcu-
lated using the Spearman-Kärber method [36] and
reported as the reciprocal of the dilution (after account-
ing for addition of virus) that decreased the plaque
count by at least 50%.
Ethical approval
The animal protocol was approved by the CBER Insti-
tutional Animal Care and Use Committee (IACUC; FDA,
USA). The use of human serum samples was approved by
the Research Involving Human Subjects Committee
(RIHSC; FDA, USA).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JB, BT, KP, and HM were responsible for design and conception of the study. JV,
BT, and HM performed the qPCR-based neutralization assay. TM, SA, LC, and JB
Varada et al. Virology Journal 2013, 10:195 Page 11 of 11
http://www.virologyj.com/content/10/1/195performed the plaque-reduction neutralization analysis. JB, KP, and HM prepared
the manuscript. All authors approved the final version of the manuscript.Acknowledgements
This study was funded by a contract (Interagency Agreement Number 224-10-
1018) from the Division of Microbiology and Infectious Diseases (DMID, NIAID,
NIH, USA). We thank Sonnie Kim Grossman (DMID) for her support. J. V. was
supported by an Oak Ridge Institute of Science and Education Fellowship through
funds provided by DMID. We are grateful to Shuang Tang and Vladimir Lugovtsev
for their critical review of this manuscript.
Author details
1Laboratory of DNA Viruses, Division of Viral Products, OVRR, CBER, FDA,
Bethesda, MD 20892, USA. 2Laboratory of Pediatric and Respiratory Viral
Diseases, Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892,
USA. 3Present affiliation: Weldon School of Biomedical Engineering, Purdue
University, West Lafayette, IN, USA.
Received: 17 April 2013 Accepted: 11 June 2013
Published: 15 June 2013References
1. Hall CB: The burgeoning burden of respiratory syncytial virus among
children. Infect Disord Drug Targets 2012, 12:92–97.
2. Tregoning JS, Schwarze J: Respiratory viral infections in infants: causes,
clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010,
23:74–98.
3. Walsh EE, Falsey AR: Respiratory syncytial virus infection in adult
populations. Infect Disord Drug Targets 2012, 12:98–102.
4. Mufson MA, Orvell C, Rafnar B, Norrby E: Two distinct subtypes of human
respiratory syncytial virus. J Gen Virol 1985, 66(Pt 10):2111–2124.
5. Glezen WP, Taber LH, Frank AL, Kasel JA: Risk of primary infection and
reinfection with respiratory syncytial virus. Am J Dis Child 1986,
140:543–546.
6. Ventre K, Randolph AG: Ribavirin for respiratory syncytial virus infection
of the lower respiratory tract in infants and young children. Cochrane
Database Syst Rev 2007, 1:CD000181.
7. Wu H, Pfarr DS, Losonsky GA, Kiener PA: Immunoprophylaxis of RSV
infection: advancing from RSV-IGIV to palivizumab and motavizumab.
Curr Top Microbiol Immunol 2008, 317:103–123.
8. Graham BS: Biological challenges and technological opportunities for
respiratory syncytial virus vaccine development. Immunol Rev 2011,
239:149–166.
9. Hurwitz JL: Respiratory syncytial virus vaccine development. Expert Rev Vaccines
2011, 10:1415–1433.
10. Beeler JA, Eichelberger MC: Influenza and respiratory syncytial virus (RSV)
vaccines for infants: safety, immunogenicity, and efficacy. Microb Pathog
2013, 55:9–15.
11. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH: Field evaluation
of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus
vaccine in a pediatric population. Am J Epidemiol 1969, 89:449–463.
12. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G:
Respiratory virus immunization. I. A field trial of two inactivated respiratory
virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-
precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969,
89:435–448.
13. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE: An
epidemiologic study of altered clinical reactivity to respiratory syncytial (RS)
virus infection in children previously vaccinated with an inactivated RS
virus vaccine. Am J Epidemiol 1969, 89:405–421.
14. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH:
Respiratory syncytial virus disease in infants despite prior administration of
antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422–434.
15. Prince GA, Hemming VG, Horswood RL, Chanock RM: Immunoprophylaxis
and immunotherapy of respiratory syncytial virus infection in the cotton
rat. Virus Res 1985, 3:193–206.
16. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ, Collins AP, Hughes M,
Jebbett J: Monoclonal antibodies protect against respiratory syncytial virus
infection in mice. Immunology 1984, 52:137–142.17. Walsh EE, Schlesinger JJ, Brandriss MW: Protection from respiratory
syncytial virus infection in cotton rats by passive transfer of monoclonal
antibodies. Infect Immun 1984, 43:756–758.
18. Coates HV, Alling DW, Chanock RM: An antigenic analysis of respiratory
syncytial virus isolates by a plaque reduction neutralization test. Am J
Epidemiol 1966, 83:299–313.
19. Anderson LJ, Hierholzer JC, Bingham PG, Stone YO: Microneutralization
test for respiratory syncytial virus based on an enzyme immunoassay.
J Clin Microbiol 1985, 22:1050–1052.
20. Zielinska E, Liu D, Wu HY, Quiroz J, Rappaport R, Yang DP: Development of
an improved microneutralization assay for respiratory syncytial virus by
automated plaque counting using imaging analysis. Virol J 2005, 2:84.
21. van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W,
Widjojoatmodjo MN: An improved respiratory syncytial virus
neutralization assay based on the detection of green fluorescent protein
expression and automated plaque counting. Virol J 2012, 9:253.
22. Rubino KL, Nicholas JA: A novel, spectrophotometric microneutralization
assay for respiratory syncytial virus. J Virol Methods 1992, 39:55–67.
23. Cheng X, Munoz MG, Zhou H, Jin H: Expression of beta-galactosidase by
recombinant respiratory syncytial viruses for microneutralization assay.
J Virol Methods 2002, 105:287–296.
24. Chen M, Chang JS, Nason M, Rangel D, Gall JG, Graham BS, Ledgerwood JE:
A flow cytometry-based assay to assess RSV-specific neutralizing
antibody is reproducible, efficient and accurate. J Immunol Methods 2010,
362:180–184.
25. Yuan L, Zhang X, Chang M, Jia C, Hemmingsen SM, Dai H: A new
fluorescent quantitative PCR-based in vitro neutralization assay for white
spot syndrome virus. J Virol Methods 2007, 146:96–103.
26. Kramski M, Drozd A, Lichtfuss GF, Dabrowski PW, Ellerbrok H: Rapid
detection of anti-Vaccinia virus neutralizing antibodies. Virol J 2011, 8:139.
27. Teferedegne B, Lewis AM Jr, Peden K, Murata H: Development of a
neutralization assay for influenza virus using an endpoint assessment
based on quantitative reverse-transcription PCR. PLoS One 2013, 8:e56023.
28. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, Aitken JA,
Patel A, DeVincenzo JP: Comparison of a real-time reverse transcriptase
PCR assay and a culture technique for quantitative assessment of viral
load in children naturally infected with respiratory syncytial virus.
J Clin Microbiol 2005, 43:2356–2362.
29. Beeler JA, van Wyke CK: Neutralization epitopes of the F glycoprotein of
respiratory syncytial virus: effect of mutation upon fusion function.
J Virol 1989, 63:2941–2950.
30. Andrewes CH, Elford WJ: Observations on anti-phage sera. I: "The
percentage law". Br J Exp Pathol 1933, 14:367–376.
31. Klasse PJ, Sattentau QJ: Occupancy and mechanism in antibody-mediated
neutralization of animal viruses. J Gen Virol 2002, 83:2091–2108.
32. Walls HH, Harmon MW, Slagle JJ, Stocksdale C, Kendal AP: Characterization
and evaluation of monoclonal antibodies developed for typing influenza
A and influenza B viruses. J Clin Microbiol 1986, 23:240–245.
33. Feldman SA, Audet S, Beeler JA: The fusion glycoprotein of human
respiratory syncytial virus facilitates virus attachment and infectivity via
an interaction with cellular heparan sulfate. J Virol 2000, 74:6442–6447.
34. Mbiguino A, Menezes J: Purification of human respiratory syncytial virus:
superiority of sucrose gradient over percoll, renografin, and metrizamide
gradients. J Virol Methods 1991, 31:161–170.
35. Murata H, Teferedegne B, Lewis AM Jr, Peden K: A quantitative PCR assay for
SV40 neutralization adaptable for high-throughput applications.
J Virol Methods 2009, 162:236–244.
36. Cohen BJ, Audet S, Andrews N, Beeler J: Plaque reduction neutralization test
for measles antibodies: description of a standardised laboratory method for
use in immunogenicity studies of aerosol vaccination. Vaccine 2007,
26:59–66.
doi:10.1186/1743-422X-10-195
Cite this article as: Varada et al.: A neutralization assay for respiratory
syncytial virus using a quantitative PCR-based endpoint assessment.
Virology Journal 2013 10:195.
